Helicore Biopharma develops glucose-dependent insulinotropic peptide (GIP) antagonist therapies for obesity treatment.

Light Horse Therapeutics develops small molecule therapeutics using a proprietary platform that identifies novel functional domains in disease-critical targets.

Antag Therapeutics is a biopharmaceutical company developing treatments for obesity and cardiometabolic diseases, focusing on injectable therapies like their novel GIPR antagonist, AT-7687.

Pep2Tango Therapeutics Inc. is a biotechnology company developing innovative peptides targeting multiple receptors to treat obesity and related conditions.

858 Therapeutics is a biotechnology company developing small molecule therapeutics for oncology and immunology, with a lead asset, ETX-19477, in Phase 1 trials for advanced solid tumors.

Nouscom is a clinical-stage immuno-oncology company specializing in off-the-shelf and personalized cancer immunotherapies using a proprietary viral vector platform.

Gate Bioscience is a biotechnology company that has developed a scientific platform to create Molecular Gates, small molecules that target and eliminate disease-causing extracellular proteins, and has raised $60M in a Series A funding round to advance its proprietary Molecular Gate Discovery Platform.

Tentarix Biotherapeutics is a biotechnology company that uses its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics.